Previous studies have reported that PD-L1 expression upregulation in tumor cells mediates immune tolerance and reduces tumor-infiltrating T cell killing ability, which may be responsible for resistance to molecular targeted drugs 31-33. This evidence concerns the gene CD274 and neoplasm.